Modulation of transthyretin expression
US9816092B2 · kind B2 · utility
2Cited by
4References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 23, 2016 |
| Grant date | Nov 14, 2017 |
| Priority date | — |
| Expiry date | Jun 23, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.